Barry Gorlitsky, MD
Nephrology · Greenville, SCNPI 1881823276
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $178,137 of the $195,446 with a category attached, or 91.1%. Amgen accounts for 97.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $62,482 and has fallen 67.1% since, to $20,547 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $450.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$190K
- Abbott$2K
- AstraZeneca$1K
- Johnson & Johnson$375
- Mozarc Medical US LLC$351
- GSK$207
- plus $1K from 18 others
Across 162 payments — averaging $17,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.7M
- Vertex$720K
- AstraZeneca$184K
- Boehringer Ingelheim International GmbH$117K
- Beigene, Ltd.$99K
- Beigene USA, Inc.$42K
- plus $35K from 2 others
What the payments were for
- Consulting fees$3,0542%
- Speaking & faculty fees$178,13791%
- Travel & lodging$8,4244%
- Food & beverage$5,5533%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 322 | $189,830 |
| Abbott | 2 | $2,125 |
| AstraZeneca | 39 | $1,227 |
| Johnson & Johnson | 1 | $375 |
| Mozarc Medical US LLC | 6 | $351 |
| GSK | 6 | $207 |
| Mallinckrodt Enterprises LLC | 9 | $205 |
| Akebia Therapeutics Inc | 8 | $164 |
| Otsuka America Pharmaceutical, Inc. | 11 | $139 |
| Baxter Healthcare | 3 | $133 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $128 |
| Vifor Pharma, Inc. | 6 | $96 |
| Mallinckrodt Hospital Products Inc. | 2 | $89 |
| Travere Therapeutics, Inc. | 3 | $78 |
| Medtronic | 1 | $53 |
| OPKO Pharmaceuticals, LLC | 2 | $47 |
| Fresenius USA Marketing, Inc. | 1 | $40 |
| Bayer | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Novo Nordisk | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$186,647
- ALERE CHOLESTECH LDX$2,125
- FARXIGA$512
- INVOKANA$375
- BENLYSTA$125
- Palindrome$123
How this compares
$195,446 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 189 | $170,608 |
| FarxigaDapagliflozin Propanediol | 89 | $77,777 |
| OzempicSemaglutide | 27 | $41,095 |
| TrulicityDulaglutide | 22 | $20,674 |
| JanuviaSitagliptin Phosphate | 18 | $17,049 |
| GemtesaVibegron | 15 | $15,243 |
| KerendiaFinerenone | 13 | $14,670 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $13,775 |
| EntrestoSacubitril/Valsartan | 11 | $11,278 |
| ProsolParenteral Amino Acid 20% No.1 | 52 | $9,258 |
| Sevelamer Carbonate | 30 | $5,302 |
| Clonidine | 32 | $3,352 |
| Olmesartan Medoxomil | 123 | $2,716 |
| Torsemide | 110 | $2,073 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $1,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,227 | $91,552106 claims |
| Novo NordiskOzempic | $18 | $41,09527 claims |
| BayerKerendia | $37 | $14,67013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Greenville
- Blake ShustermanGreenville$66K
- Tarak ShahGreenville$9K
- Istvan BognarGreenville$6K
- William WardGreenville$5K
- Carlos ZayasGreenville$5K
- Hari Naga GarapatiGreenville$5K
- Kaye ChristopherGreenville$5K
- Willy TsaiGreenville$4K
- Kelly HeegardGreenville$4K
- Chitra NathanGreenville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.